ALK-Abelló A/S (ALK-B.CO)

128.70 +1.20 (+0.94%) At close: 04:59PM CEST

ALK-Abelló A/S

Bøge Allé 6-8
Horsholm 2970
Denmark
45 45 74 75 76
https://www.alk.net

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,824

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Claus Steensen Solje	Executive VP, CFO & Member of Management Board	14.12M	N/A	1972
Mr. Søren Daniel Niegel	Executive VP of Commercial Operations & Member of Management Board	5.33M	N/A	1971
Dr. Henriette Mersebach	Executive VP Research & Development & Member of Management Board	6.16M	N/A	1971
Ms. Katja Barnkob Thalund	Project Director of Global CMC Development & Employee-elected Director	350k	N/A	1969
Mr. Peter Halling	President & CEO	N/A	N/A	1977
Mr. Per Plotnikof	VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR	N/A	N/A	N/A
Prof. Hendrik Kees Kam Nolte M.D., Ph.D.	Senior Vice President of Research & Development - North America and International Markets	N/A	N/A	N/A
Mr. Christian G. Houghton	Head of Product Supply	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Corporate governance

ALK-Abelló A/S’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 9; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.